MED12L Gene Alterations Define Aggressive BRCA2-Mutant Prostate Cancers
|Study ID||Alternative Stable ID||Type|
Germline mutation of BRCA2 increases the lifetime risk of developing prostate cancer (PCa) by over 700%. BRCA2-mutant PCa have poorer prognosis than sporadic PCa, with rapid development of metastatic, castrate-resistant prostate cancer (mCRPC) and 5-year cancer-specific survival rates of ~50-60%1-4. Despite this, unique genomic driver events that explain the aggressiveness of localized BRCA2-mutant PCa are lacking. We used whole-genome sequencing to fully characterize 14 BRCA2-mutant PCa and demonstrate that BRCA2-mutant PCa is associated with increased genetic instability and a mutually exclusive mutational burden when compared to sporadic PCa. Importantly, BRCA2-mutated cancers are defined by unique copy number gains and hypomethylation events, including alterations in the MED12L/MED12 axis, which are found solely in mCRPC and are enriched in PCa tumours harbouring aggressive intraductal carcinoma (IDC-P) pathologic sub-types. Our findings begin to explain the clinical entity of BRCA2-mutated PCa as these tumours have a unique and aggressive genotype de novo, associated with IDC-P ... (Show More)
Study Datasets 5 datasets.
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
Aligned sequence data from 14 Prostate cancer samples with BRCA2 mutations
single nucleotide variant calls from somatic sniper, vcf format
single nucleotide variant calls from somatic sniper, vcf format. input for subclonal reconstruction
structural variant calls from Delly, vcf format
Raw Array data from the CPCGene BRCA study
|Affymetrix OncoScan FFPE Express||48|
Who archives the data?